epidem
ebola
viru
ebov
swept
western
africa
begin
decemb
worst
outbreak
deadli
hemorrhag
fever
viru
record
histori
individu
infect
die
current
estim
survivor
addit
tragic
loss
life
mani
survivor
suffer
sequela
aros
recov
ebov
infect
sequela
includ
visual
problem
hear
loss
bodi
ach
sever
fatigu
memori
loss
moreov
infecti
ebov
shown
persist
semen
six
month
ebov
rna
found
semen
late
nine
month
postinfect
least
one
case
sexual
transmiss
report
current
approv
drug
treat
ebov
patient
consequ
recent
outbreak
sever
agent
administ
patient
compassion
care
basi
includ
zmapp
cocktail
monoclon
antibodi
hyperimmun
serum
sever
low
molecular
weight
antivir
drug
addit
therapeut
antibodi
recent
describ
two
novel
low
molecular
weight
viral
rna
polymeras
inhibitor
develop
differ
approach
screen
us
food
drug
administr
fda
approv
drug
antiebov
activ
goal
repurpos
approv
drug
combin
approv
drug
use
prophylact
andor
therapeut
advent
futur
outbreak
clomiphen
surfac
two
independ
screen
fdaapprov
drug
antiebov
activ
block
ebov
entri
infect
tissu
cultur
cell
provid
protect
mous
model
ebov
diseas
clomiphen
select
estrogen
receptor
modul
use
treat
femal
infertil
due
anovul
also
propos
drug
revers
impot
men
due
low
testosteron
level
current
use
offlabel
men
hypogonad
found
howev
clomiphen
exert
antiebov
activ
cell
cultur
irrespect
express
estrogen
receptor
alpha
andor
beta
subunit
instead
clomiphen
like
exert
antiebov
activ
cation
amphiphil
drug
accumul
endolysosom
site
ebov
fusion
cytoplasm
entri
similar
cation
amphiphil
drug
clomiphen
block
late
step
complex
process
ebov
genom
gain
access
host
cell
cytoplasm
initi
replic
like
block
fusion
ebov
endolysosom
membran
clomiphen
citrat
clinicallyadminist
drug
formul
test
date
antiebov
activ
mixtur
two
diastereoisom
transclomiphen
enclomiphen
cisclomiphen
zuclomiphen
wherea
enclomiphen
exhibit
high
antiestrogen
properti
zuclomiphen
two
isom
also
differ
pharmacokinet
properti
exampl
zuclomiphen
longer
halflif
serum
persist
tissu
longer
period
time
enclomiphen
could
therefor
propos
zuclomiphen
major
contributor
advers
side
effect
seen
individu
given
clomiphen
citrat
convers
enclomiphen
would
impart
fewer
side
effect
due
featur
well
abil
rais
testosteron
level
enclomiphen
current
clinic
develop
treatment
secondari
hypogonad
low
testosteron
level
differ
pharmacolog
featur
enclomiphen
zuclomiphen
ongo
clinic
develop
enclomiphen
compar
effect
clomiphen
isom
ebov
entri
replic
found
clomiphen
enclomiphen
zuclomiphen
two
primari
metabolit
block
ebov
entri
replic
similar
level
compar
clomiphen
enclomiphen
zuclomiphen
display
similar
dose
profil
block
ebov
entri
replic
test
two
cell
type
glycoprotein
two
isol
ebov
well
marburg
viru
clomiphen
enclomiphen
zuclomiphen
suppli
repro
therapeut
inc
woodland
tx
usa
compound
stock
mm
prepar
dimethyl
sulfoxid
dmso
store
room
temperatur
use
hek
cell
obtain
univers
virginia
tissu
cultur
facil
atcc
charlottesvil
va
usa
vero
cell
atcc
maintain
growth
medium
high
glucos
dulbecco
modifi
eagl
medium
dmem
supplement
lglutamin
sodium
pyruv
antibioticantimycot
gibco
life
technolog
univers
virginia
tissu
cultur
facil
charlottesvil
va
usa
hek
vero
cell
contain
either
supplement
calf
serum
sc
hyclon
thermofish
scientif
waltham
usa
fetal
bovin
serum
fb
seradigm
univers
virginia
tissu
cultur
facil
charlottesvil
va
usa
respect
transcriptionreplicationcompet
virallik
particl
trvlp
prepar
biosafeti
level
condit
describ
briefli
prepar
stock
confluent
hek
cell
seed
h
prior
six
well
plate
transfect
pcaggsnp
pcaggsl
tetracistron
minigenom
plasmid
polymeras
use
miru
madison
wi
usa
minigenom
plasmid
encod
renilla
luciferas
well
matrix
protein
gp
envelop
protein
ebov
h
post
transfect
medium
well
replac
ml
fresh
growth
medium
contain
fb
h
transfect
medium
contain
trvlp
harbor
renilla
luciferasecontain
minigenom
harvest
pool
clear
cellular
debri
centrifug
min
g
stock
prepar
serial
passag
stock
hek
target
cell
freshli
transfect
pcaggsnp
pcaggsl
trvlp
store
ice
use
within
two
week
entri
report
virallik
particl
vlp
bear
gp
mayinga
makona
ebov
marburg
viru
marv
angola
isol
gift
dr
christoph
broder
uniform
servic
univers
health
scienc
bethesda
md
usa
prepar
essenti
describ
previou
work
brief
confluent
hek
cell
transfect
cdna
encod
ebov
marv
gp
although
util
studi
vlp
use
monitor
vlp
bind
traffick
within
cell
describ
cell
medium
collect
h
posttransfect
clear
cellular
debri
vlp
clear
medium
pellet
sucros
cushion
centrifug
resuspend
hm
buffer
mm
hepe
mm
me
mm
nacl
ph
repellet
final
vlp
pellet
resuspend
start
volum
medium
sucrosehm
total
protein
concentr
vlp
determin
bicinchonin
acid
bca
assay
entryreport
vlp
prepar
assess
western
blot
analys
presenc
indic
glycoprotein
well
ebov
titer
vero
cell
confirm
entri
compet
entryreport
vlp
frozen
singl
use
aliquot
use
within
four
month
infect
hek
cell
trvlp
assay
describ
minor
modif
brief
prepar
target
cell
hek
cell
seed
parallel
opaqu
white
plate
bd
falcon
thermofish
scientif
waltham
usa
trvlp
cell
viabil
assay
clearbottom
plate
assess
cell
densiti
transfect
efficaci
h
post
seed
cell
approxim
confluent
cell
transfect
per
well
ng
pcaggsnp
ng
ng
ng
pcaggsl
ng
use
plasmid
necessari
target
cell
support
entri
replic
incom
trvlp
assess
transfect
efficaci
provid
neg
control
well
plate
transfect
green
fluoresc
protein
gfp
express
plasmid
place
pcaggsl
h
post
transfect
medium
remov
target
hek
cell
pretreat
indic
concentr
indic
drug
dmso
mock
dilut
omem
gibco
life
technolog
via
univers
virginia
tissu
cultur
facil
charlottesvil
va
usa
h
incub
assess
trvlp
infect
pretreat
solut
remov
replac
trvlp
dilut
growth
medium
contain
sc
indic
concentr
indic
drug
dmso
mock
cell
incub
h
incub
medium
replac
fresh
growth
medium
contain
sc
renillaglo
substrat
promega
madison
wi
usa
ad
well
plate
immedi
analyz
glomax
plate
reader
assess
cell
viabil
pretreat
solut
remov
replac
fresh
growth
medium
contain
sc
indic
concentr
indic
drug
dmso
mock
cell
incub
h
incub
medium
replac
fresh
growth
medium
contain
sc
celltiterglo
promega
ad
well
plate
place
jitterbug
orbit
shaker
boekel
scientif
thermofish
scientif
waltham
usa
set
rpm
min
room
temperatur
rt
plate
incub
rt
min
luminesc
signal
detect
use
synergi
ht
biotek
winooski
vt
usa
plate
reader
vlp
entri
assay
perform
describ
minor
modif
brief
vero
cell
seed
per
well
clear
plate
h
post
seed
cell
confluent
cell
treat
indic
drug
indic
concentr
dmso
mock
dilut
omem
h
incub
vlp
dilut
omem
presenc
indic
drug
indic
concentr
dmso
mock
bound
cell
spinfect
g
h
cell
incub
h
incub
substrat
life
technolog
thermofish
scientif
waltham
usa
load
cell
previous
describ
mm
instead
mm
probenecid
mp
biomed
thermofish
scientif
waltham
usa
load
buffer
cell
incub
overnight
rt
fix
analyz
flow
cytometri
describ
measur
cell
viabil
vero
cell
seed
grown
opaqu
white
plate
treat
vlp
entri
vlp
ad
load
overnight
incub
rt
see
medium
remov
cell
replac
fresh
medium
per
well
microlit
per
well
ad
plate
place
jitterbug
orbit
shaker
rpm
min
rt
plate
incub
rt
min
luminesc
signal
detect
use
biotek
synergi
ht
plate
reader
trvlp
infect
vlp
entri
raw
data
normal
mock
infectionentri
signal
percent
inhibit
infectionentri
determin
graphpad
prism
use
perform
nonlinear
regress
analys
log
agonist
vs
respons
variabl
slope
percent
inhibit
valu
inhibitori
concentr
valu
interpol
base
regress
curv
valu
automat
gener
graphpad
program
ecanyth
use
determin
valu
base
hill
slope
valu
regress
analysi
clomiphen
mixtur
two
stereoisom
enclomiphen
zuclomiphen
primari
metabolit
lesser
extent
first
compar
abil
clomiphen
enclomiphen
zuclomiphen
block
ebov
use
trvlp
life
cycl
model
system
describ
watt
hoenen
seen
figur
isom
clomiphen
enclomiphen
zuclomiphen
well
metabolit
display
dosedepend
inhibit
trvlp
infect
similar
seen
parent
mixtur
clomiphen
cell
pretreat
h
increas
concentr
compound
dose
five
form
clomiphen
show
approxim
equal
potenc
reduc
trvlp
renilla
luciferas
signal
approxim
parallel
set
cell
show
evid
cytotox
form
clomiphen
figur
previou
find
indic
clomiphen
block
ebov
infect
block
entri
viral
particl
cell
cytoplasm
effect
appear
level
fusion
membran
viral
particl
limit
membran
niemannpick
diseas
type
posit
endolysosom
site
ebov
fusion
therefor
compar
effect
clomiphen
enclomiphen
zuclomiphen
ebov
entri
use
entri
report
vlp
describ
previous
concentr
clomiphen
isom
enclomiphen
zuclomiphen
well
metabolit
isom
block
vlp
entri
figur
evid
cytotox
figur
system
appear
potent
form
clomiphen
figur
like
assaydepend
result
potent
trvlp
assay
figur
elabor
section
enclomiphen
zuclomiphen
exhibit
differ
pharmacolog
properti
notabl
zuclomiphen
longer
halflif
evid
suggest
zuclomiphen
compon
respons
advers
side
effect
seen
mice
treat
clomiphen
therefor
compar
clomiphen
enclomiphen
zuclomiphen
detail
effect
trvlp
infect
vlp
entri
first
compar
clomiphen
enclomiphen
trvlp
infect
vlp
entri
system
use
eightpoint
dose
respons
curv
seen
figur
clomiphen
enclomiphen
show
similar
dosedepend
inhibit
trvlp
infect
experi
calcul
clomiphen
enclomiphen
clomiphen
enclomiphen
also
show
similar
dosedepend
inhibit
vlp
entri
system
clomiphen
enclomiphen
figur
similar
result
seen
compar
eight
dose
clomiphen
zuclomiphen
trvlp
infect
figur
vlp
entri
figur
assay
valu
eightpoint
dose
respons
curv
figur
figur
figur
given
tabl
observ
valu
hek
cell
good
agreement
clomiphen
vs
enclomiphen
clomiphen
vs
zuclomiphen
trvlp
infect
vs
vlp
entri
assay
moreov
rang
valu
calcul
effect
clomiphen
ebov
infect
vero
cell
gfpencod
nativ
ebov
mayinga
previou
work
use
authent
ebov
lab
show
clomiphen
block
infect
multipl
cell
type
includ
vero
kidney
liver
huvec
endotheli
cell
strain
filovirus
test
three
strain
ebola
viru
two
marburg
viru
use
assay
conduct
laboratori
begin
test
whether
enclomiphen
show
similar
breadth
filoviru
inhibitor
first
use
trvlp
system
compar
efficaci
clomiphen
enclomiphen
vero
cell
trvlp
experi
present
thu
far
conduct
hek
cell
optim
assay
highli
transfect
multipl
plasmid
need
produc
trvlp
assay
lifecycl
capac
vero
cell
also
good
target
assay
seen
figur
clomiphen
enclomiphen
block
trvlp
infect
vero
cell
similar
dose
profil
current
trvlp
system
util
plasmid
encod
protein
mayinga
isol
ebov
oftus
refer
strain
therefor
util
entri
report
vlp
accommod
glycoprotein
virus
ask
whether
abil
enclomiphen
block
ebov
entri
extend
filovirus
seen
figur
enclomiphen
exert
similar
effect
clomiphen
block
entri
mediat
gp
makona
ebov
isol
caus
outbreak
western
africa
seen
figur
enclomiphen
inhibit
entri
mediat
marburg
viru
gp
repres
differ
genu
within
filoviru
famili
similar
effect
clomiphen
clomiphen
emerg
two
independ
screen
fdaapprov
drug
antiebov
activ
tissu
cultur
cell
also
found
provid
protect
femal
mice
challeng
lethal
dose
ebov
analys
demonstr
clomiphen
block
ebov
entri
host
cell
cytoplasm
viru
particl
transport
endolysosom
site
ebov
fusion
cytoplasm
entri
henc
clomiphen
interfer
process
ebov
fusion
endolysosom
membran
clomiphen
use
treat
femal
infertil
mixtur
two
stereoisom
enclomiphen
zuclomiphen
sinc
zuclomiphen
thought
impart
side
effect
enclomiphen
develop
treatment
secondari
hypogonad
low
testosteron
main
object
studi
assess
abil
enclomiphen
zuclomiphen
block
ebov
infect
individu
isom
might
offer
differ
advantag
differ
clinic
set
found
enclomiphen
zuclomiphen
highli
similar
clomiphen
abil
block
trvlp
infect
vlp
entri
valid
surrog
assay
ebov
infect
ebov
entri
respect
clomiphen
enclomiphen
zuclomiphen
inhibit
vlp
entri
trvlp
infect
similar
valu
test
equal
effect
two
cell
type
entri
mediat
three
filovir
gp
also
block
ebov
trvlp
infect
vlp
entri
condit
test
therefor
propos
like
clomiphen
enclomiphen
zuclomiphen
potenti
panfilovir
inhibitor
multipl
cell
type
approxim
individu
die
recent
outbreak
makona
ebov
anoth
surviv
infect
tragic
mani
survivor
display
post
ebola
viru
diseas
syndrom
includ
visual
problem
hear
loss
excess
fatigu
addit
infecti
ebov
found
semen
six
month
rais
concern
sexual
transmiss
henc
drug
accumul
tissu
eye
male
reproduct
tract
could
particularli
help
certain
ebola
viru
survivor
respect
interest
mice
enclomiphen
zuclomiphen
persist
eye
male
reproduct
tract
longer
tissu
zuclomiphen
maintain
higher
level
enclomiphen
zuclomiphen
also
found
persist
brain
wherea
enclomiphen
clomiphen
provid
protect
lethal
mous
model
ebov
infect
administ
femal
mice
dose
mgkg
day
postinfect
appar
ill
effect
surviv
mice
maximum
serum
concentr
cmax
mgkg
dose
intraperiton
administr
ip
clomiphen
femal
mice
lisa
johansen
person
commun
henc
blockad
ebov
infect
tissu
cultur
cell
valu
report
clomiphen
isom
block
ebov
vlp
entri
trvlp
infect
tabl
standard
dose
clomiphen
treat
femal
infertil
mgday
per
os
oral
dose
report
cmax
valu
sum
enclomiphen
zuclomiphen
rang
tabl
vero
cell
antiebov
activ
therefor
potenti
treatment
acut
ebov
infect
higher
dose
clomiphen
would
certainli
need
like
combin
antiebov
drug
human
equival
dose
mous
dose
employ
adult
weigh
kg
would
mg
clomiphen
everi
day
respect
noteworthi
higher
dose
clomiphen
mgday
administ
nonrespond
anovul
femal
consider
higher
cmax
valu
obtain
patient
administ
standard
dose
clomiphen
mg
intraven
administr
iv
instead
oral
rout
tabl
henc
conceiv
higher
dose
clomiphen
could
administ
perhap
part
cocktail
treat
acut
ebov
infect
irrespect
util
clomiphen
acut
ebov
infect
given
persist
clomiphen
isom
eye
male
reproduct
tract
clomiphen
alon
combin
may
util
manag
post
ebola
viru
diseas
symptom
ebov
survivor
exampl
enclomiphen
zuclomiphen
accumul
respect
harderian
gland
locat
orbit
uveal
tract
mous
eye
similar
accumul
zuclomiphen
seen
tissu
male
mous
reproduct
tract
accrual
occur
human
standard
dose
mg
per
day
per
os
clomiphen
contain
isom
could
suffici
reach
antivir
level
eye
male
reproduct
tract
level
would
like
suffici
clomiphen
given
higher
dose
andor
combin
anoth
antiebov
agent
interestingli
sperm
seen
test
epididym
male
mice
treat
day
mgkgday
zuclomiphen
sinc
two
isom
clomiphen
hydroxyl
metabolit
block
ebov
vlp
entri
replic
cell
cultur
protect
effect
clomiphen
mous
model
could
due
form
metabol
en
zuclomiphen
human
wellcharacter
differ
isom
shown
mice
therefor
interest
compar
efficaci
individu
clomiphen
isom
mous
model
ebov
infect
studi
rel
efficaci
eye
reproduct
tract
especi
reveal
shown
like
parent
mixtur
two
isom
clomiphen
hydroxyl
metabolit
block
entri
replic
ebov
vlp
cell
cultur
activ
isom
shown
two
cell
type
three
filovir
gp
isom
clomiphen
accumul
tissu
eye
male
reproduct
tract
henc
propos
clomiphen
fdaapprov
drug
provid
protect
mous
model
ebola
viru
diseas
remain
consider
antiebov
agent
especi
manag
post
ebola
viru
diseas
syndrom
includ
visual
problem
risk
sexual
transmiss
especi
consider
part
potenti
drug
cocktail
